DCOY logo

DECOY THERAPEUTICS INC

DCOYNASDAQ
πŸ† #5325 by market capUS Equity
$0.87β€”
Last available close Β· quote unavailable
πŸ””
Track DCOY
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 9.4%
14dβ–Ό 22.7%
30dβ–Ό 12.1%
ytdβ–Ό 88.7%
1yβ–Ό 91.7%
🏦Market Cap
$441,214
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
-2678.4%
Thin
πŸ’΅FCF Margin
-3053.6%
Thin
βš–οΈP/S Ratio
1.4x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
β€”
52-Week Range
$0.80 – $16.92
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
531,967
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$307,430
P/E Ratio
-0.0
P/S Ratio
1.4x
EPS (TTM)
$-19.59
Dividend Yield
0.00%
Dilution (1yr)
+6544.6%
DCOY logo

DECOY THERAPEUTICS INC

DCOY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$13Mβ–² +120.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$5Mβ–² +6.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
532Kβ–² +6544.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$11Mβ–² +$8M YoY
StockOtter Β· stockotter.space

About DECOY THERAPEUTICS INC

Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.